Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

Multiple Myeloma (MM)

Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma

Blood Cancer J

Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Morán-Segura CM, Nguyen JV, Lekakis L, Fernandez-Pol S, Samraj AN, Naresh KN, Vazquez-Martinez M, Baz RC, Spiegel JY, Mikkilineni L, Gubatan JM, Sidana S, de Menezes Silva Corraes A, Kalariya NM, Patel KK, Shim KG, Fonseca R, Ferreri C, Voorhees PM, Richard S, Valdes CR, Sireesha Asoori, Wolf JL, Cowan AJ, Sborov DW, Locke FL, Lin Y, Wang Y, Hansen DK

doi: 10.1038/s41408-024-01167-8

Leukemia

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study

Leukemia

Ortí G, Peczynski C, Boreland W, O'Reilly M, von Bonin M, Balduzzi A, Besley C, Kalwak K, Ryhänen S, Güngör T, Wynn RF, Bader P, Mielke S, Blaise D, Amrolia P, Yakoub-Agha I, Calkoen F, Schubert ML, Potter V, Pichler H, Kröger N, Kwon M, Sengeloev H, Torrent A, Chalandon Y, van Gorkom G, Koenecke C, Graham C, Schoemans H, Moiseev I, Penack O, Peric Z

doi: 10.1038/s41375-024-02467-5

Lymphoma

Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS

Br J Haematol

Hossain NM, Ahn KW, Patel J, Lian Q, Abid B, Al Nughmush A, Bacher U, Bi X, Hashmi SK, Hilal T, Husnain M, Khimani F, Maziarz RT, Modi D, Ram R, Rizzieri D, Sica RA, Steinberg A, Vij R, Shadman M, Turtle C, Hamadani M, Herrera AF

doi: 10.1111/bjh.70020

Leukemia

Early versus late infectious complications following chimeric antigen receptor-modified T-cell therapy

Leuk Lymphoma

Bindal P, Trottier CA, Elavalakanar P, Dodge LE, Kim S, Logan E, Ma S, Liegel J, Arnason J, Alonso CD

doi: 10.1080/10428194.2024.2439513

Lymphoma

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Br J Haematol

de la Iglesia-San Sebastián I, López-Esteban M, Bastos-Oreiro M, Fernández de Córdoba-Oñate S, Gutierrez M, Carbonell D, Bailén R, Gómez-Centurión I, Fernández-Caldas P, Castilla L, Anguita J, Kwon M, García-Sanz R, Buño I, Martínez-Laperche C

doi: 10.1111/bjh.19916

Further Publications

Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy

Haematologica

Boardman AP, Gutgarts V, Flynn J, Devlin SM, Goldman A, Tomas AA, Fein JA, Slingerland JB, Parascondola A, Lin RJ, Scordo M, Dahi PB, Giralt S, Palomba ML, Salles G, Nath K, Walji M, Corona M, Park JH, Shah GL, Perales MA, Jaffer-Sathick I, Shouval R

doi: 10.3324/haematol.2024.286021

Lymphoma

Severe cytopenia after chimeric antigen receptor-T cell driven by large granular lymphocytes and responsive to steroids

Br J Haematol

Capes A, Morin A, Banet A, Suner L, Ricard L, Corre E, Brissot E, Stocker N, Marjanovic Z, Sarkozy C, Mohty M, Malard F

doi: 10.1111/bjh.19822

Lymphoma

Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes

Br J Haematol

Barone A, De Philippis C, Stella F, Dodero A, Sarina B, Pennisi M, Santoro A, Carlo-Stella C, Guidetti A, Bramanti S, Corradini P

doi: 10.1111/bjh.70010

EHA/ICML 2025

Lymphoma

Related content

Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study

Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS

Early versus late infectious complications following chimeric antigen receptor-modified T-cell therapy

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy

Severe cytopenia after chimeric antigen receptor-T cell driven by large granular lymphocytes and responsive to steroids

Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes

Expanding the Curative Potential of CAR T-Cell Therapy